Clinical Trial Update: Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating paclitaxel in patients with metastatic, recurrent, or unresectable esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Theradex | Conditions: Esophageal Cancer | Phase 2 | Status: UNKNOWN